Malcolm Lloyd-Smith insider trades: Neurocrine Biosciences (NBIX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Malcolm reports to the SEC
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 8, 2023 | NBIX | ↓ Sell | 15,318 | $102.64 | $1.6M | Direct | Feb 8, 2023 (0d) |
| Jan 31, 2023 | NBIX | ↓ Sell | 1,666 | $110.02 | $183K | Direct | Feb 2, 2023 (2d) |
| Aug 12, 2022 | NBIX | ↓ Sell | 21,533 | $105.95 | $2.3M | Direct | Aug 16, 2022 (4d) |
| Feb 8, 2022 | NBIX | ↓ Sell | 3,382 | $80.48 | $272K | Direct | Feb 9, 2022 (1d) |
| Jul 27, 2021 | NBIX | ↓ Sell | 16,709 | $93.80 | $1.6M | Direct | Jul 29, 2021 (2d) |
| Feb 10, 2021 | NBIX | ↓ Sell | 1,700 | $119.96 | $204K | Direct | Feb 12, 2021 (2d) |
| Feb 8, 2021 | NBIX | ↓ Sell | 4,126 | $116.26 | $480K | Direct | Feb 9, 2021 (1d) |
| Jan 26, 2021 | NBIX | ↓ Sell | 18,670 | $119.97 | $2.2M | Direct | Jan 27, 2021 (1d) |
| Nov 12, 2020 | NBIX | ↓ Sell | 2,257 | $90.73 | $205K | Direct | Nov 16, 2020 (4d) |
| Aug 5, 2020 | NBIX | ↓ Sell | 2,257 | $118.86 | $268K | Direct | Aug 7, 2020 (2d) |
| Apr 24, 2020 | NBIX | ↓ Sell | 1,934 | $99.45 | $192K | Direct | Apr 28, 2020 (4d) |
| Feb 10, 2020 | NBIX | ↓ Sell | 29,984 | $104.52 | $3.1M | Direct | Feb 11, 2020 (1d) |
| Feb 6, 2020 | NBIX | ↓ Sell | 3,438 | $102.38 | $352K | Direct | Feb 7, 2020 (1d) |
| Oct 14, 2019 | NBIX | ↓ Sell | 9,956 | $90.85 | $904K | Direct | Oct 16, 2019 (2d) |
| Feb 6, 2019 | NBIX | ↓ Sell | 920 | $83.58 | $77K | Direct | Feb 8, 2019 (2d) |
| Feb 5, 2019 | NBIX | ↓ Sell | 1,272 | $88.14 | $112K | Direct | Feb 6, 2019 (1d) |
| Nov 7, 2018 | NBIX | ↓ Sell | 9,000 | $110.01 | $990K | Direct | Nov 8, 2018 (1d) |
| Feb 5, 2018 | NBIX | ↓ Sell | 960 | $83.19 | $80K | Direct | Feb 7, 2018 (2d) |
| Jan 2, 2018 | NBIX | ↓ Sell | 18,084 | $77.52 | $1.4M | Direct | Jan 4, 2018 (2d) |
| May 19, 2017 | NBIX | ↓ Sell | 9,960 | $53.63 | $534K | Direct | May 23, 2017 (4d) |
| Apr 12, 2017 | NBIX | ↓ Sell | 13,065 | $50.42 | $659K | Direct | Apr 13, 2017 (1d) |
| Feb 7, 2017 | NBIX | ↓ Sell | 843 | $43.35 | $37K | Direct | Feb 8, 2017 (1d) |
| Sep 1, 2016 | NBIX | ↓ Sell | 9,000 | $50.00 | $450K | Direct | Sep 2, 2016 (1d) |
| May 31, 2016 | NBIX | ↓ Sell | 9,000 | $50.00 | $450K | Direct | Jun 2, 2016 (2d) |
| Jul 22, 2013 | CADX | ↓ Sell | 14,000 | $7.85 | $110K | Direct | Jul 23, 2013 (1d) |
| Jun 10, 2013 | CADX | ↓ Sell | 4,000 | $7.44 | $30K | Direct | Jun 11, 2013 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NBIX insiders
Open-market trades in the last 12 months
About Malcolm Lloyd-Smith's insider trades
Malcolm Lloyd-Smith is Chief Integration Officer at Neurocrine Biosciences (NBIX). Since Jun 10, 2013, Malcolm has reported no open-market purchases and 26 sales worth $18.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (12 filings), option exercises (11 filings), shares withheld for taxes (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.